Source: Annual Congress 2005 - Pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Brugger, M. Beghetti, D. Tassaux, A. Battisti, P. Jolliet (Geneva, Switzerland). Comparative effects of inhaled nitric oxide and aerosolized iloprost during vasoreactivity testing in chronic pulmonary hypertension. Eur Respir J 2005; 26: Suppl. 49, 3614

Member's Comments

No comment yet.

Related content which might interest you: Acute vasoresponsiveness to inhaled nitric oxide in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 The acute haemodynamic effects of 'pulsed' inhaled nitric oxide and iv epoprostenol in patients with pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 The effect of inhaled nitric oxide on the cardiac performance in patients with hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003 Influence of inhaled nitric oxide on plasma endothelin-1 in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003 Inhaled nitric oxide (NO) for vasoreactivity testing in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 Haemodynamic testing in primary pulmonary hypertension - effects of nitric oxide, iloprost and oxygen Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001 Feasibility of home treatment with inhaled nitric oxide for primary pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001 Combination of inhaled nitric oxide and an endothelinA-receptor antagonist in acute pulmonary thromboembolism Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003 Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Acute vasoreactivity testing with sildenafil vs nitric oxide in patients with PAH Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models Year: 2012 Inhaled iloprost reverses chronic experimental pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 353s Year: 2005 Infused nitric oxide in experimental pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 348s Year: 2007 Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002 Bronchial nitric oxide output predicts responsiveness to inhaled steroids in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 429s Year: 2004 Nitric oxide vs prostacyclin in chronic high-flow pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002 Effect of the Asp298 variant of endothelial nitric oxide synthase on acute pulmonary vasodilator testing response in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Effect of once-daily inhaled glucocorticosteroid administration on exhaled nitric oxide in controlled asthma patients Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Nitric oxide in acute testing in patients with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004